id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-284163-3jmqzemf	Seffer, Malin-Theres	Heparin 2.0: A New Approach to the Infection Crisis	2020-07-02		.txt	text/plain	2982	156	43	This narrative review will give a brief overview regarding some of the extracorporeal devices that could be used to treat COVID-19 patients, including the Seraph® 100 Microbind® Affinity Blood Filter, produced by ExThera Medical (Martinez, CA, USA), first licensed in the European Economic Area in 2019. Bacteria, viruses, fungi, and toxins have been shown to bind to the immobilized heparin in a similar way to the interaction with heparan sulfate on the cell surface. Of note, it has recently been demonstrated that SARS-CoV-2 attaches to heparin through its surface protein Spike 1 receptor-binding domain [21] . The Seraph ® 100 Microbind ® Affinity Blood Filter is an extracorporeal hemoperfusion device whose functional core, that is, polyethylene beads (diameter of 0.3 mm) with immobilized heparin bound to it, mimics a naturally mammalian cell surface (Fig. 1) . Cytokines in blood from septic patients interact with surface-immobilized heparin	./cache/cord-284163-3jmqzemf.txt	./txt/cord-284163-3jmqzemf.txt